The ONCO/Reveal Solid Tumor Panel is a robust 47-gene assay that simultaneously tests for key mutations present in solid tumors, including NSCLC, colorectal, pancreatic, GIST, thyroid cancer, melanomas and gliomas. Additionally, genes with potential importance in immuno-oncology such as POLD1 and POLE are analyzed. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology for efficient single-tube target enrichment.
- Requires as little as 2.5 ng of input DNA
- Detection of 1% allele frequency in somatic cancers
- Single sample / single well assay technology for enhanced sensitivity
- Automatable sample processing